Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline - GBI Research Reports

Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline

Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline - GBI Research Reports
Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline
Published Feb 01, 2010
181 pages — Published Feb 01, 2010
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

SummaryGBI Research, the leading business intelligence provider, has released its latest research, 'Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline', which provides an insight into the global biotechnology industry and analyzes the competitive positioning of the top 10 companies in the industry. This pharmaceutical and healthcare report estimates the market size of the global biotechnology industry and its future prospects. It benchmarks the leading companies in the biotechnology industry on selected parameters to analyze their competitive positioning in the market. The report analyzes the future landscape of the biotechnology industry by forecasting the revenues of leading companies to 2012. For each company the report analyzes the financial strength, product portfolio, pipeline strength and therapeutic focus of its R&D activities. It critically examines the strengths and weaknesses of individual companies and the opportunities and threats facing them. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.ScopeThe report analyses the competitive landscape of the biotechnology industry, R&D strategies and pipeline of the top 10 players, and strengths, weaknesses, opportunities and threats facing these companies. Its scope includes - Market size of the global biotechnology industry and coverage of the changing competitive landscape from 2008 to 2012.- Review of key industry drivers and restraints which are likely to impact the global biotechnology industry in the future.- Analysis of the competitive positioning of the top 10 biotechnology companies globally.- Analysis of pipeline products in the global biotech market by therapy area like cancer, infectious diseases, respiratory disorders, autoimmune disorders, and product classes.- Financial analysis including annual revenues of top 10 companies from 2004 to 2008, with forecasts to 2012.- SWOT analysis, DuPont analysis and financial benchmarking of the top 10 biotech companies.- Analysis of the therapeutic focus, marketed products and product pipeline of top 10 biotech companies.Reasons to buyThe report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:- Develop a clear knowledge and understanding of the competitive landscape and how this will change in the coming years. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.- Effectively plan your M&A and partnership strategies by identifying companies with the most promising pipeline.- Make more informed business decisions from the insightful and in-depth analysis of the key strategies to be followed by competitors. - Effectively plan your investment strategies by identifying companies with maximum investment potential.- Identify key winners and losers and who is best positioned to take advantage of the emerging market opportunities.

  
Source:
Document ID
GBIHC008MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents411
1.1 List of Tables93
1.2 List of Figures123
2 Introduction152
2.1 GBI Research Report Guidance161
3 Global Biotechnology Industry Market Characterization177
3.1 Global Biotechnology Industry Market Size171
3.2 Top 10 Companies Market Forecast182
3.3 Therapeutic Focus of the Biotechnology Industry202
3.4 Global Biotechnology Industry Growth Drivers and Restraints221
3.4.1 Growth Drivers221
3.4.1.1 High Unmet Need Driving Market Growth221
3.4.1.2 Huge Investments in R&D Resulting In Strong Product Pipeline 221
3.4.1.3 Strong Growth in the Market for Cancer and Autoimmune Diseases221
3.4.1.4 Lack of Patent Expiry Ensures a Continuous Stream Of Revenue221
3.4.1.5 Increasing Interest of Big Pharma Companies in Biotechnology Industry 231
3.4.2 Restraints231
3.4.2.1 High Cost of Treatment of Biologics231
3.4.2.2 Increasing Incidences of Adverse Side Effects231
3.4.2.3 Threat from Biosimilars231
4 Top 10 Biotechnology Companies Competitive Landscape246
4.1 Competitive Landscape Framework241
4.2 Financial Benchmarking251
4.2.1 Earnings per Share 261
4.2.2 Net Profit Margin261
4.2.3 Current Ratio271
4.2.4 Debt to Equity ratio271
4.2.5 Asset Turnover Ratio281
4.3 R&D Productivity Framework282
5 Global Biotechnology Industry Strategic Consolidations303
5.1 Pharma Biotech Space Deals Analysis (2008)301
5.2 Increasing Interest of Big Pharma Companies in the Biotech Industry312
6 Top 10 Biotechnology Companies Amgen3317
6.1 Company Overview331
6.1.1 Introduction331
6.1.2 Business Description331
6.2 Strategic Positioning341
6.2.1 SWOT Analysis341
6.2.1.1 Strengths - Strong Marketed and Pipeline Products Drive Amgen s Revenues 341
6.2.1.2 Weaknesses - Market Is Declining for Its Key Products like Aranesp and Epogen351
6.2.1.3 Opportunities - High Growth in Oncology Therapeutics Market Presents Immense Opportunities351
6.2.1.4 Threats - Safety Concerns Are Looming Over the Use of Esas in Patients351
6.3 Financial Analysis361
6.3.1 Revenue Analysis and Forecasts363
6.3.2 Ratio Analysis391
6.3.2.1 Equity Ratios391
6.3.2.2 Profitability Ratios401
6.3.2.3 Liquidity Ratios411
6.3.2.4 Leverage Ratios421
6.3.2.5 Efficiency Ratios421
6.3.3 DuPont Analysis431
6.4 Marketed Products441
6.4.1 Key Marketed Products441
6.4.1.1 Enbrel441
6.4.1.2 Aranesp441
6.4.1.3 Epogen441
6.4.1.4 Neulasta441
6.4.1.5 Neupogen441
6.5 R&D Strategies451
6.5.1 Therapeutic Focus451
6.5.2 R&D Productivity461
6.6 Product Pipeline471
6.6.1 Overview471
6.6.2 Key Pipeline Products481
6.6.2.1 Denosumab481
6.6.2.2 Motesanib481
6.6.2.3 Aranesp481
6.6.2.4 Sensipar481
6.7 Licensing Agreements491
6.7.1 Overview491
7 Top 10 Biotechnology Companies Genentech (Roche)5016
7.1 Company Overview501
7.1.1 Introduction501
7.1.2 Business Description501
7.2 Strategic Positioning511
7.2.1 SWOT Analysis511
Strengths - Monoclonal Antibodies in Cancer Therapeutics Market Driving Growth 511
7.2.1.2 Weaknesses - Relationship with Roche Might Restrict Geographical Expansion511
7.2.1.3 Opportunities - Promising future in oncology therapeutics and small molecule therapies521
7.2.1.4 Threats Entry of Biosimilars in Oncology Pose a Threat To Company s Revenues 521
7.3 Financial Analysis521
7.3.1 Revenue Analysis and Forecasts523
7.3.2 Ratio Analysis551
7.3.2.1 Equity Ratios551
7.3.2.2 Profitability Ratios561
7.3.2.3 Liquidity Ratios571
7.3.2.4 Leverage Ratios581
7.3.2.5 Efficiency Ratios591
7.3.3 DuPont Analysis591
Marketed Products601
7.4.1 Key Marketed Products601
7.4.1.1 Avastin601
7.4.1.2 Rituxan601
7.4.1.3 Herceptin601
7.4.1.4 Lucentis601
7.5 R&D Strategies611
Therapeutic Focus611
7.5.2 R&D Productivity611
7.6 Product Pipeline621
7.6.1 Overview622
7.6.2 Key Pipeline Products641
7.6.2.1 Avastin641
7.6.2.2 Ocrelizumab (2nd Generation Anti-D20)641
7.6.2.3 Tarceva641
7.7 Licensing Agreements641
7.7.1 Overview642
8 Top 10 Biotechnology Companies Gilead Sciences6614
8.1 Company Overview661
Introduction661
8.1.2 Business Description661
8.2 Strategic Positioning671
8.2.1 SWOT Analysis671
8.2.1.1 Strengths - Gilead Is the Market Leader in the Global HIV Therapeutics Market671
8.2.1.2 Weaknesses - Product Portfolio of Gilead Lacks Diversification 671
8.2.1.3 Opportunities - Strong Growth Is Expected In the HIV Therapeutics Market681
8.2.1.4 Threats - Competitors Are Collaborating to Challenge Gilead s Leadership681
8.3 Financial Analysis681
8.3.1 Revenue Analysis and Forecasts683
8.3.2 Ratio Analysis711
8.3.2.1 Equity Ratios711
8.3.2.2 Profitability Ratios712
8.3.2.3 Liquidity Ratios731
8.3.2.4 Leverage Ratios741
8.3.2.5 Efficiency Ratios741
8.3.3 DuPont Analysis751
8.4 Marketed Products761
8.4.1 Key Marketed Products761
8.4.1.1 Truvada761
Atripla761
8.4.1.3 Viread761
8.5 R&D Strategies761
8.5.1 Therapeutic Focus761
8.5.2 R&D Productivity771
8.6 Product Pipeline781
8.6.1 Overview781
8.6.2 Key Pipeline Products791
8.6.2.1 Aztreonam791
8.6.2.2 Elvitegravir 791
8.6.2.3 Darusentan791
8.7 Licensing Agreements791
8.7.1 Overview791
9 Top 10 Biotechnology Companies UCB Pharma8014
9.1 Company Overview801
9.1.1 Introduction801
9.1.2 Business Description801
9.2 Strategic Positioning811
9.2.1 SWOT Analysis811
9.2.1.1 Strengths - Complete Focus on Biopharmaceuticals to Drive Long Term Strategy811
9.2.1.2 Weaknesses - Product Recalls and Rejections Affecting Company s Brand Value811
9.2.1.3 Opportunities - Company s Pipeline to Present Opportunities for Growth821
9.2.1.4 Threats - Generics Affecting the Growth Prospects of Global Epilepsy Market821
9.3 Financial Analysis821
9.3.1 Revenue Analysis and Forecasts823
9.3.2 Ratio Analysis851
9.3.2.1 Equity Ratios851
9.3.2.2 Profitability Ratios861
9.3.2.3 Liquidity Ratios871
9.3.2.4 Leverage Ratios881
9.3.2.5 Efficiency Ratios881
9.3.3 DuPont Analysis891
9.4 Marketed Products901
9.4.1 Key Marketed Products901
9.4.1.1 Keppra/Keppra XR and Vimpat901
Neupro901
9.4.1.3 Cimzia901
9.5 R&D Strategies901
9.5.1 Therapeutic Focus901
9.5.2 R&D Productivity902
9.6 Product Pipeline921
9.6.1 Overview921
9.6.2 Key Pipeline Products931
9.6.2.1 Brivaracetam931
9.6.2.2 Vimpat931
9.6.2.3 Epratuzumab931
9.7 Licensing Agreements931
9.7.1 Overview931
10 Top 10 Biotechnology Companies Genzyme9415
10.1 Company Overview941
10.1.1 Introduction941
10.1.2 Business Description941
10.2 Strategic Positioning951
10.2.1 SWOT Analysis951
10.2.1.1 Strengths - Broad Product Base and Orphan Drug Status Strengthens Company s Positioning951
10.2.1.2 Weaknesses - Withdrawl of Evoltra in Europe Will Affect Revenues961
10.2.1.3 Opportunities - Cancer Therapeutics Market Will Present Growth Opportunities961
10.2.1.4 Threats - Competition Is Likely to Increase for Company s Lead Products961
10.3 Financial Analysis971
10.3.1 Revenue Analysis and Forecasts972
10.3.2 Ratio Analysis991
10.3.2.1 Equity Ratios991
10.3.2.2 Profitability Ratios1001
10.3.2.3 Liquidity Ratios1011
10.3.2.4 Leverage Ratios1021
10.3.2.5 Efficiency Ratios1021
10.3.3 DuPont Analysis1021
Marketed Products1031
10.4.1 Key Marketed Products1031
10.4.1.1 Cerezyme1031
10.4.1.2 Fabrazyme1041
10.4.1.3 Renagel and Renvela1041
10.5 R&D Strategies1041
10.5.1 Therapeutic Focus1041
10.5.2 R&D Productivity1051
10.6 Product Pipeline1061
10.6.1 Overview1061
10.6.2 Key Pipeline Products1071
10.6.2.1 Alemtuzumab1071
10.6.2.2 Mipomersen1071
10.6.2.3 Clolar1071
10.7 Licensing Agreements1071
10.7.1 Overview1072
11 Top 10 Biotechnology Companies Biogen Idec10914
11.1 Company Overview1091
11.1.1 Introduction1091
11.1.2 Business Description1091
11.2 Strategic Positioning1101
11.2.1 SWOT Analysis1101
11.2.1.1 Strengths - Aggressive Licensing Activities Complementing For Lack Of Global Presence1101
11.2.1.2 Weaknesses - Excessive Reliance on A Few Products for Revenue Growth1101
11.2.1.3 Opportunities - Cancer Therapeutics and Multiple Sclerosis Market Can Drive Growth1111
11.2.1.4 Threats - Competition Getting Stiff for Company s Key Products1111
11.3 Financial Analysis1111
11.3.1 Revenue Analysis and Forecasts1113
11.3.2 Ratio Analysis1141
11.3.2.1 Equity Ratios1141
11.3.2.2 Profitability Ratios1142
11.3.2.3 Liquidity Ratios1161
11.3.2.4 Leverage Ratios1171
11.3.2.5 Efficiency Ratios1171
11.3.3 DuPont Analysis1181
11.4 Marketed Products1191
11.4.1 Key Marketed Products1191
11.4.1.1 Avonex1191
11.4.1.2 Tysabri1191
11.4.1.3 Rituxan1191
11.5 R&D Strategies1191
11.5.1 Therapeutic Focus1191
11.5.2 R&D Productivity1201
11.6 Product Pipeline1211
11.6.1 Overview1211
11.6.2 Key Pipeline Products1221
11.6.2.1 Ocrelizumab1221
11.6.2.2 PEG IFN and BG-12 1221
11.6.2.3 Rituxan1221
11.7 Licensing Agreements1221
11.7.1 Overview1221
12 Top 10 Biotechnology Companies CSL Limited12314
12.1 Company Overview1231
12.1.1 Introduction1231
12.1.2 Business Description1231

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline" Feb 01, 2010. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Top-10-Biotechnology-Companies-SWOT-Analysis-Competitive-Benchmarking-Financial-Analysis-and-R-D-Pipeline-2115-28>
  
APA:
GBI Research Reports. (2010). Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline Feb 01, 2010. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Top-10-Biotechnology-Companies-SWOT-Analysis-Competitive-Benchmarking-Financial-Analysis-and-R-D-Pipeline-2115-28>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.